The U.S. Food and Drug Administration (FDA) has approved a second opioid overdose reversal agent for over-the-counter, nonprescription use.
ReVive, a 3-milligram naloxone hydrochloric nasal spray from Harm Reduction Therapeutics Inc., was given the green light by the FDA on July 28. The new spray will be available in early 2024 primarily to state governments and harm reduction organizations nationwide at “costs lower than other opioid antagonist nasal sprays,” according to the company. At least 200,000 doses will be made available at no cost.
In March, the FDA approved Narcan, a 4-milligram naloxone hydrochloride nasal spray for over-the-counter use.